Value-based health care: issues for pharmaceutical companies
Michael Lampert, Ropes & Gray health care partner, discusses issues facing pharmaceutical companies with the move towards value-based health care models.
Trending Similar Videos
China’s new cybersecurity law
Mimi Yang, a Ropes & Gray government enforcement partner in Hong Kong, provides an overview of China’s new cybersecurity law (CSL), which came into effect in June 2017.
Value-based health care: compliance infrastructure
Brett Friedman, Ropes & Gray health care partner, discusses the impact to compliance organizations as payment models transition from traditional fee-for-service to value-based.
False Claims Act: Implied Certification Theory
Kirsten Mayer, Ropes & Gray litigation & enforcement partner, examines the implied certification theory of liability under the False Claims Act.
FTC's merger remedies study
Jonathan Klarfeld, Ropes & Gray antitrust partner, discusses key takeaways and likely impacts of the Federal Trade Commission's recent divestiture study.
Anti-corruption & international risk developments
Alex Rene, co-chair of Ropes & Gray’s anti-corruption / international risk practice and managing partner of the firm’s Washington, D.C. office, discusses recent FCPA enforcement activity as well as international risk challenges facing companies.
Value-based health care: the role of payors
Bill Knowlton, Ropes & Gray health care partner, examines the critically important role of payors in value-based health care programs.